FDA issues Safety Alert for clarithromycin
Editor's Note
The Food and Drug Administration (FDA) on February 22 issued a Safety Alert for clarithromycin (Biaxin) because of the potential increased risk of heart problems or death associated with this antibiotic in patients with heart disease.
A large clinical trial with 10-year follow-up found an unexpected increase in deaths among coronary heart disease patients 1 year or longer after receiving a 2-week course of clarithromycin.
As a result, the FDA is advising prescribers to consider using other antibiotics in such patients and has added the study results to the drug label.
Posted 02/22/2018] AUDIENCE: Health Professional, Internal Medicine, Cardiology, Patient ISSUE: FDA is advising caution before prescribing the antibiotic clarithromycin (Biaxin) to patients with heart disease because of a potential increased risk of heart problems or death that can occur years later.
Free Daily News
- Study: COVID-19's impact on oncological surgery offers lessons for future crises
- Study links pandemic stress to persistent increases in nursing-sensitive quality indicators
- Save the date for the 2025 OR Business Management Conference
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025
- IV fluid shortage drives innovation in hospital hydration practices
- FDA Class 1 recalls target anesthesia workstations, ambulatory infusion pumps, ventilators
- Five leadership lessons from an ASC CEO